Subscribe to RSS

DOI: 10.1055/s-0045-1815704
KI-67 Immunohistochemical Expression in Lung Tissue of Rats under Chronic Renal Failure
Authors
Funding and Sponsorship This work was supported by Bukhara State Medical Institute.
Abstract
Background
Chronic kidney disease (CKD) is associated with systemic complications, including pulmonary alterations due to kidney–lung crosstalk. This study evaluates Ki-67 immunohistochemical expression in rat lung tissue to assess cellular proliferative activity under experimental chronic renal failure (CRF) conditions, considering age-related variations.
Materials and Methods
Outbred male rats (n = 150, aged 6, 9, and 12 months) were divided into control and experimental groups. CRF was induced via repeated intramuscular injections of 50% glycerol (0.5 mL twice weekly for 1 month). Alveolar lung tissues were fixed, sectioned, and stained for Ki-67 using the 3,3′-Diaminobenzidine method. Quantitative analysis was performed with QuPath software (v0.4.0) to calculate proliferative indices. Data were analyzed using two-way ANOVA with post-hoc tests (p <0.05).
Results
In controls, Ki-67 proliferative indices declined with age: 55.86% at 6 months, 52.32% at 9 months, and 23.44% at 12 months. Under CRF, indices were significantly suppressed: 21.75, 11.06, and 2.32%, respectively (p <0.01 vs. controls), indicating impaired cellular renewal.
Conclusion
Experimental CRF exacerbates age-dependent reductions in lung cell proliferation, highlighting mechanisms, such as inflammation and hypoxia in pulmonary pathology. These findings underscore the need for targeted interventions in CKD-related lung dysfunction.
Keywords
lung tissue - regeneration - aging - cell proliferation - chronic renal failure - immunohistochemistry - Ki-67Authors' Contributions
T.T.B.U. collected the data. A.D.B. prepared the manuscript draft. K.D.A. reviewed and edited the manuscript. All authors have read and approved the final version of the manuscript.
Artificial intelligence (AI) tools, including language models, have been used solely for linguistic purposes, such as translation and grammatical correction. No part of the scientific content, data analysis, interpretation, or conclusions was generated using AI.
Declaration of GenAI Use
Artificial intelligence (AI) tools, including language models, have been used solely for linguistic purposes, such as translation and grammatical correction. No part of the scientific content, data analysis, interpretation, or conclusions was generated using AI.
Compliance with Ethical Principles
Ethical approval was obtained from the Local Ethics Committee of Bukhara State Medical Institute (Protocol No. 5, November 27, 2024; Extract No. 12028 dated December 02, 2024).
Publication History
Article published online:
12 January 2026
© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Bikbov B, Purcell CA, Levey AS. et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395 (10225): 709-733
- 2 Brück K, Stel VS, Gambaro G. et al. CKD prevalence varies across the European general population: results from the European CKD Burden Consortium. J Am Soc Nephrol 2016; 27 (07) 2135-2147
- 3 Duan JY, Duan GC, Wang CJ. et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey. BMC Nephrol 2020; 21 (01) 115
- 4 Dudko MYu, Kotenko ON, Shutov EV. et al. Epidemiology of chronic kidney disease among residents of Moscow. Clin Nephrol 2019; 11 (03) 37-41
- 5 Fraser SDS, Roderick PJ. Kidney disease in the Global Burden of Disease Study 2017. Nat Rev Nephrol 2019; 15 (04) 193-194
- 6 Muiru AN, Charlebois ED, Balzer LB. et al. The epidemiology of chronic kidney disease (CKD) in rural East Africa: a population-based study. PLoS One 2020; 15 (03) e0229649
- 7 Gembillo G, Calimeri S, Tranchida V. et al. Lung dysfunction and chronic kidney disease: a complex network of multiple interactions. J Pers Med 2023; 13 (02) 286
- 8 Nemmar A, Karaca T, Beegam S, Yuvaraju P, Yasin J, Ali BH. Lung oxidative stress, DNA damage, apoptosis, and fibrosis in adenine-induced chronic kidney disease in mice. Front Physiol 2017; 8: 896
- 9 Peng CK, Huang KL, Lan CC. et al. Experimental chronic kidney disease attenuates ischemia-reperfusion injury in an ex vivo rat lung model. PLoS One 2017; 12 (03) e0171736
- 10 Jiang Q, Yang Q, Zhang C. et al. Nephrectomy and high-salt diet inducing pulmonary hypertension and kidney damage by increasing Ang II concentration in rats. Respir Res 2024; 25 (01) 288
- 11 Bollenbecker S, Heitman K, Czaya B. et al. Phosphate induces inflammation and exacerbates injury from cigarette smoke in the bronchial epithelium. Sci Rep 2023; 13 (01) 4898
- 12 Ali SA, Kadry MO, Hammam O, Hassan SA, Abdel-Megeed RM. Ki-67 pulmonary immunoreactivity in silver nanoparticles toxicity: size-rate dependent genotoxic impact. Toxicol Rep 2022; 9: 1813-1822
- 13 Komai M, Mihira K, Shimada A. et al. Pathological study on epithelial-mesenchymal transition in silicotic lung lesions in rat. Vet Sci 2019; 6 (03) 70
- 14 Hill NR, Fatoba ST, Oke JL. et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS One 2016; 11 (07) e0158765
- 15 Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020; 98 (4S): S1-S115
- 16 Tuttle KR, Bakris GL, Bilous RW. et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 2019; 42 (05) 617-628
- 17 Foreman KJ, Marquez N, Dolgert A. et al. Forecasting life expectancy, years of life lost, and mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392 (10159): 2052-2090
- 18 Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ 2018; 96 (06) 414-422D
- 19 Markova TN, Kosova EV, Mishchenko NK. Pituitary disorders in patients with end-stage chronic renal failure. Probl Endokrinol (Mosk) 2024; 69 (06) 37-46
- 20 Fu Q, Colgan SP, Shelley CS. Hypoxia: the force that drives chronic kidney disease. Clin Med Res 2016; 14 (01) 15-39
- 21 Husain-Syed F, Walmrath HD, Birk HW. Lung-kidney cross-talk. In: Ronco C, Bellomo R, Kellum JA. eds. Critical Care Nephrology. 3rd ed.. Elsevier; 1044-1052
- 22 Moinard J, Guenard H, Postma DS. Membrane diffusion of the lungs in patients with chronic renal failure. Eur Respir J 1993; 6 (02) 225-230
